Alnylam Pharmaceuticals Inc (ALNY)vsVertex Pharmaceuticals Inc (VRTX)
ALNY
Alnylam Pharmaceuticals Inc
$205.52
+0.02%
HEALTHCARE · Cap: $27.50B
VRTX
Vertex Pharmaceuticals Inc
$477.10
-0.95%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 154% more annual revenue ($12.22B vs $4.80B). VRTX leads profitability with a 35.5% profit margin vs 16.0%. ALNY appears more attractively valued with a PEG of 0.37. VRTX earns a higher WallStSmart Score of 68/100 (B-).
ALNY
Strong Buy68
out of 100
Grade: B-
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.7%
Fair Value
$2613.72
Current Price
$205.52
$2408.20 discount
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$477.10
$464.16 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Every $100 of equity generates 54 in profit
Revenue surging 66.9% year-over-year
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Premium valuation, high expectations priced in
0.0% earnings growth
Elevated debt levels
Trading at 20.3x book value
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on PEG Ratio, Return on Equity, Revenue Growth. Profitability is solid with margins at 16.0% and operating margin at 17.9%. Revenue growth of 66.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : ALNY
The primary concerns for ALNY are P/E Ratio, EPS Growth, Debt/Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ALNY profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.
VRTX carries more volatility with a beta of 0.29 — expect wider price swings.
ALNY is growing revenue faster at 66.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (68/100 vs 68/100), backed by strong 16.0% margins and 66.9% revenue growth. VRTX offers better value entry with a 49.1% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?